{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:40:14Z","timestamp":1794591614823,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273234"],"award-info":[{"award-number":["82273234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972232"],"award-info":[{"award-number":["81972232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81830102"],"award-info":[{"award-number":["81830102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"crossref","award":["21ZR1412200"],"award-info":[{"award-number":["21ZR1412200"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Key Clinical Specialty Construction Project","award":["shslczdzk02401"],"award-info":[{"award-number":["shslczdzk02401"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04404-4","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:30:01Z","timestamp":1761042601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiao-Yong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Tao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Long","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"2","key":"4404_CR1","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4404_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","volume":"379","author":"H Zhang","year":"2016","unstructured":"Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 2016;379(2):198\u2013205.","journal-title":"Cancer Lett"},{"issue":"2","key":"4404_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95\u2013111.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"4404_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crad.2010.11.002","volume":"66","author":"SY Park","year":"2011","unstructured":"Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011;66(4):322\u20138.","journal-title":"Clin Radiol"},{"issue":"11","key":"4404_CR5","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1245\/s10434-009-0631-1","volume":"16","author":"SB Choi","year":"2009","unstructured":"Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16(11):3048\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"4404_CR6","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"4404_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"16_suppl","key":"4404_CR8","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","volume":"42","author":"RS Finn","year":"2024","unstructured":"Finn RS, Ueno M, Yoo C, Ren Z, Furuse J, Kelley RK, et al. Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC). J Clin Oncol. 2024;42(16_suppl):4093.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4404_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 2020;20(1):1105.","journal-title":"BMC Cancer"},{"issue":"6","key":"4404_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, et al. A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888\u201394.","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"4404_CR11","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1200\/JCO.2021.39.15_suppl.4080","volume":"39","author":"L Villanueva","year":"2021","unstructured":"Villanueva L, Lwin Z, Chung HCC, Gomez-Roca CA, Longo F, Yanez E, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. J Clin Oncol. 2021;39(15_suppl):4080.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4404_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1039\/c1mt00041a","volume":"3","author":"A Zayed","year":"2011","unstructured":"Zayed A, Jones GD, Reid HJ, Shoeib T, Taylor SE, Thomas AL, et al. Speciation of oxaliplatin adducts with DNA nucleotides. Metallomics. 2011;3(10):991\u20131000.","journal-title":"Metallomics"},{"issue":"7","key":"4404_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/sj.bjc.6603334","volume":"95","author":"J Harder","year":"2006","unstructured":"Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer. 2006;95(7):848\u201352.","journal-title":"Br J Cancer"},{"issue":"4","key":"4404_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00280-009-1069-7","volume":"65","author":"JS Jang","year":"2010","unstructured":"Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol. 2010;65(4):641\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4404_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/annonc\/mdz058","volume":"30","author":"ST Kim","year":"2019","unstructured":"Kim ST, Kang JH, Lee J, Lee HW, Oh SY, Jang JS, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol. 2019;30(5):788\u201395.","journal-title":"Ann Oncol"},{"issue":"9","key":"4404_CR16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15(9):1339\u201343.","journal-title":"Ann Oncol"},{"issue":"2","key":"4404_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353\u201363.","journal-title":"J Hepatol"},{"issue":"1","key":"4404_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 2023;8(1):106.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4404_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr. 2020;9(4):414\u201324.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"10","key":"4404_CR20","doi-asserted-by":"publisher","first-page":"103919","DOI":"10.1016\/j.esmoop.2024.103919","volume":"9","author":"M Ueno","year":"2024","unstructured":"Ueno M, Morizane C, Ikeda M, Ozaka M, Nagashima F, Kataoka T, et al. Phase I\/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808\/NCCH1817, SNIPE). ESMO Open. 2024;9(10):103919.","journal-title":"ESMO Open"},{"key":"4404_CR21","doi-asserted-by":"publisher","first-page":"vii68","DOI":"10.1093\/annonc\/mdl955","volume":"17 Suppl 7","author":"F Verderame","year":"2006","unstructured":"Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol. 2006;17 Suppl 7:vii68-72.","journal-title":"Ann Oncol"},{"issue":"8","key":"4404_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"D Malka","year":"2014","unstructured":"Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardi\u00e8re C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819\u201328.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4404_CR23","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","volume":"16","author":"JW Valle","year":"2015","unstructured":"Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16(8):967\u201378.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4404_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma. Drugs. 2019;79(6):665\u201374.","journal-title":"Drugs"},{"key":"4404_CR25","doi-asserted-by":"publisher","first-page":"107692","DOI":"10.1016\/j.pharmthera.2020.107692","volume":"219","author":"K Fousek","year":"2021","unstructured":"Fousek K, Horn LA, Palena C. Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther. 2021;219:107692.","journal-title":"Pharmacol Ther"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04404-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04404-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04404-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:04:34Z","timestamp":1761087874000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04404-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4404"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04404-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all amendments were reviewed and approved by the Ethics Committee of each participating site, including the Ethics Committee of Zhongshan Hospital, Fudan University (approval number: B2020-038). The trial was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines. Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"573"}}